Alyeska Investment Group
IMDX

Alyeska Investment Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Alyeska Investment Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Buy
+840,777
New +$4.88M 0.01% 532

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FOR
Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

Alyeska Investment Group's IMDX Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 840,777 shares worth $2.76M. The stake represents 0.01% of the portfolio and ranks #532 among its holdings.

41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Alyeska Investment Group held 840,777 shares of Insight Molecular Diagnostics worth $2.76M as of Q1 2026.
  • Insight Molecular Diagnostics was a new Alyeska Investment Group position in Q1 2026.
  • Insight Molecular Diagnostics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #532 holding.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.